The company states: “On April 21, after a decades-long career, Melissa Baird, Chief Operating Officer of Hims & Hers Health, announced her intention to transition into an advisory role with Hims ...

Hims & Hers has shown explosive growth, with potential revenue of $2.5B in FY25, trading at a low 2.4x FY25 sales. Despite the high short interest and bear arguments, HIMS' data-driven ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business, presenting a buying opportunity for long-term investors. The company is ramping up liraglutide ...

Hims & Hers Health (HIMS) stock declined about 2% yesterday. The fall came after the U.S. Food and Drug Administration (FDA) issued a warning about topical finasteride, a hair-loss treatment sold ...

But one standout stock has nearly doubled the market - over the past five years, Hims & Hers Health has surged 172% to $26.89 per share. Its momentum hasn’t stopped as it’s also gained 25.8% ...

Throughout the last three months, 13 analysts have evaluated Hims & Hers Health HIMS, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform. The treatments will each cost $ ...

Hims & Hers Health (HIMS) has emerged as a disruptive force in telehealth, leveraging technology and personalization to address highly-personal health conditions while achieving scalable ...

Hims & Hers Health has emerged as a disruptive force in telehealth, leveraging technology and personalization to address highly-personal health conditions while achieving scalable profitability ...